

Supplementary material, Appendix 1
ClinicalTrials.gov Search Results 06/25/2021

	NCT Number	Title	Other Names	Status	Study Results	Conditions	Interventions	Characteristics
1	NCT04829383	A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma	Title Acronym: AB7	Recruiting	No Results Available	•Unresectable Hepatocellular Carcinoma	•Drug: Atezolizumab •Drug: Bevacizumab	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment
2	NCT04770896	A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab	Title Acronym: IMbrave251	Recruiting	No Results Available	•Unresectable Hepatocellular Carcinoma	•Drug: Atezolizumab •Drug: Lenvatinib •Drug: Sorafenib	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment
3	NCT04541173	Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)		Recruiting	No Results Available	•Hepatocellular Carcinoma	•Other: Y-90 TARE •Drug: Atezolizumab •Drug: Bevacizumab	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment

4	NCT04857684	SBRT + Atezolizumab + Bevacizumab in Resectable HCC		Not yet recruiting	No Results Available	<ul style="list-style-type: none"> •Hepatocellular Carcinoma •Resectable Hepatocellular Carcinoma 	<ul style="list-style-type: none"> •Drug: Atezolizumab •Drug: Bevacizumab •Radiation: Stereotactic Beam Radiation Therapy (SBRT) 	<div>Study Type: Interventional</div> <div>Phase: Early Phase 1</div> <div>Study Design: <ul style="list-style-type: none"> •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment </div>
---	-------------	---	--	--------------------	----------------------	---	---	---

	NCT Number	Title	Other Names	Status	Study Results	Conditions	Interventions	Characteristics
5	NCT04563338	An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)		Not yet recruiting	No Results Available	<ul style="list-style-type: none"> •Hepatocellular Carcinoma •Non-small Cell Lung Cancer Metastatic •Liver Metastases 	<ul style="list-style-type: none"> •Drug: Atezolizumab •Drug: Bevacizumab 	<div>Study Type: Interventional</div> <div>Phase: Phase 2</div> <div>Study Design: <ul style="list-style-type: none"> •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment </div>
6	NCT04721132	Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer		Not yet recruiting	No Results Available	<ul style="list-style-type: none"> •Resectable Hepatocellular Carcinoma •Stage I Hepatocellular Carcinoma AJCC v8 •Stage IA Hepatocellular Carcinoma AJCC v8 •Stage IB Hepatocellular Carcinoma AJCC v8 •Stage II Hepatocellular Carcinoma AJCC v8 	<ul style="list-style-type: none"> •Biological: Atezolizumab •Biological: Bevacizumab •Procedure: Therapeutic Conventional Surgery 	<div>Study Type: Interventional</div> <div>Phase: Phase 2</div> <div>Study Design: <ul style="list-style-type: none"> •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment </div>

7	NCT04224636	Atezolizumab/Bevacizumab Followed by Ondemand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab	Title Acronym: DEMAND	Recruiting	No Results Available	•Hepatocellular Carcinoma Nonresectable	•Combination Product: Atezolizumab Injection, Bevacizumab Injection	Study Type: Interventional
								Phase: Phase 2
								Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment
8	NCT04732286	A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy		Recruiting	No Results Available	•Carcinoma, Hepatocellular	•Drug: Atezolizumab •Drug: Bevacizumab	Study Type: Interventional
								Phase: Phase 3
								Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment

	NCT Number	Title	Other Names	Status	Study Results	Conditions	Interventions	Characteristics
9	NCT04727307	Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial	Title Acronym: AB-LATE02	Recruiting	No Results Available	•Hepatocellular Carcinoma	•Drug: Atezolizumab (neoadjuvant) •Procedure: Percutaneous Radiofrequency •Drug: Bevacizumab (adjuvant) •Drug: Atezolizumab (adjuvant)	Study Type: Interventional
								Phase: Phase 2
								Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment
10	NCT04862949	Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC		Recruiting	No Results Available	•Advanced Hepatocellular Carcinoma	•Drug: Atezolizumab plus bevacizumab	Study Type: Observational
								Phase:
								Study Design: •Observational Model: Cohort •Time Perspective: Prospective

11	NCT04803994	The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma		Not yet recruiting	No Results Available	•Hepatocellular Carcinoma	•Drug: Atezolizumab •Drug: Bevacizumab •Procedure: TACE	<div>Study Type: Interventional</div> <div>Phase: Phase 3</div> <div>Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment</div>
12	NCT04730388	ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or	Title Acronym: HEPATOFIT	Not yet recruiting	No Results Available	•Advanced Hepatocellular Carcinoma		<div>Study Type: Observational</div> <div>Phase:</div> <div>Study Design: •Observational Model: Cohort •Time Perspective: Prospective</div>
13	NCT04487067	A Study of Atezolizumab (Tecentrig) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista	Title Acronym: AMETHISTA	Recruiting	No Results Available	•Carcinoma, Hepatocellular	•Drug: Atezolizumab •Drug: Bevacizumab	<div>Study Type: Interventional</div> <div>Phase: Phase 3</div> <div>Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment</div>
	NCT Number	Title	Other Names	Status	Study Results	Conditions	Interventions	Characteristics
14	NCT04712643	A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma		Recruiting	No Results Available	•Hepatocellular Carcinoma	•Drug: Atezolizumab •Drug: Becavizumab •Device: Transarterial chemoembolization (TACE)	<div>Study Type: Interventional</div> <div>Phase: Phase 3</div> <div>Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment</div>

15	NCT04102098	A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation	Title Acronym: IMbrave050	Recruiting	No Results Available	•Carcinoma, Hepatocellular	•Drug: Atezolizumab •Drug: Bevacizumab	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment
16	NCT04180072	Atezolizumab Plus Bevacizumab With HCC and HBV Infection		Recruiting	No Results Available	•Carcinoma, Hepatocellular	•Drug: Atezolizumab •Drug: Bevacizumab	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment
17	NCT04649489	A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT After Initial Ate/Bev		Recruiting	No Results Available	•Hepatic Portal Vein Tumor Invasion	•Drug: Atezolizumab •Procedure: Surgery	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

List of current active or inactive clinical trials with atezolizumab and bevacizumab combination lists on clinical trial.gov website